Abstract
The primary objective of early-phase (phase I, or phase I/II) clinical trials of a given anticancer agent is to determine its optimal dose (OD) to be administered to a cancer patient, so as to obtain the highest efficacy while maintaining admissible toxicity. Thus, in oncology, early-phase trials for anticancer agents are also called “dose-finding” trials. For a chemotherapeutic or cytotoxic agent, classically, the OD is determined in the phase I trial, in which toxicity alone is primarily evaluated. Here, the highest tested safe dose with tolerable toxicity, called the “maximum tolerated dose (MTD),” is determined. This approach is adopted because monotonic increases in both toxicity and efficacy with increasing dose are assumed; thus, the MTD corresponds to the recommended phase II dose, and is also expected to yield the highest efficacy among the tested doses. However, this reasoning may not hold for molecularly targeted or cytostatic agents, or for immunotherapeutic agents (IAs). The ODs of such agents are found in phase I/II trials, in which both toxicity and efficacy are evaluated to determine the dose that yields the highest efficacy and admissible toxicity, or the dose that also yields the required immune response (particularly for IAs). This distinction exists because the efficacy does not always monotonically increase with a higher dose, even if the toxicity increases in this manner. In this chapter, we overview the clinical research and development process of anticancer drugs, describe the basic concepts of early-phase trials, and outline various dose-finding designs for early-phase trials.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Berry, S.M., Carlin, B.P., Lee, J.J., Müller, P.: Chapter 3. Phase I studies. In: Berry, S.M., Carlin, B.P., Lee, J.J., Müller, P. (eds.) Bayesian Adaptive Methods for Clinical Trials, First Edition, pp. 87–135. Chapman and Hall/CRC Press, Boca Raton, FL (2010)
Braun, T.M., Alonzo, T.A.: Beyond the 3+3 method: expanded algorithms for dose-escalation in phase I oncology trials of two agents. Clin. Trials 8(3), 247–259 (2011)
Chang, M.: Adaptive Design Theory and Implementation Using SAS and R, 1st edn. Chapman and Hall/CRC Press, Boca Raton, FL (2008a)
Chang, M.: Classical and Adaptive Clinical Trial Designs Using ExpDesign Studio, 1st edn. John Wiley & Sons, Hoboken, NJ (2008b)
Cheung, Y.K.: Coherence principles in dose-finding studies. Biometrika 92(4), 863–873 (2005)
Chevret, S.: Statistical Methods for Dose-Finding Experiments, 1st edn. John Wiley & Sons, Chichester (2006)
Chow, S.-C., Chang, M.: Adaptive Design Methods in Clinical Trials, 2nd edn. Chapman and Hall/CRC Press, Boca Raton, FL (2011a)
Chow, S.-C., Chang, M.: Chapter 5. Adaptive dose-escalation trials. In: Chow, S.-C., Chang, M. (eds.) Adaptive Design Methods in Clinical Trials, Second Edition, pp. 89–104. Chapman and Hall/CRC Press, Boca Raton, FL (2011b)
Cohen, L., de Moor, C., Amato, R.J.: The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a phase I cancer clinical trial. Cancer 91(10), 1949–1955 (2001)
Couzin-Frankel, J.: Cancer immunotherapy. Science 324(6165), 1432–1433 (2013)
Crowley, J., Hoering, A.: Handbook of Statistics in Clinical Oncology, 3rd edn. Chapman and Hall/CRC Press, Boca Raton, FL (2012)
Daugherty, C., Ratain, M.J., Grochowski, E., Stocking, C., Kodish, E., Mick, R., Siegler, M.: Perceptions of cancer patients and their physicians involved in phase I trials. J. Clin. Oncol. 13(5), 1062–1072 (1995)
Edler, L., Burkholder, I.: Chapter 1. Overview of phase I trials. In: Crowley, J., Ankerst, D.P. (eds.) Handbook of Statistics in Clinical Oncology, Second Edition, pp. 1–29. Chapman and Hall/CRC Press, Boca Raton, FL (2006)
Eisenhauer, E.A., O’Dwyer, P.J., Christian, M., Humphrey, J.S.: Phase I clinical trial design in cancer drug development. J. Clin. Oncol. 18(3), 684–692 (2000)
Green, S., Benedetti, J., Crowley, J.: Clinical Trials in Oncology, 2nd edn. Chapman and Hall/CRC Press, Boca Raton, FL (2003)
Hirakawa, A., Sato, H., Daimon, T., Matsui, S.: Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted Agents. Springer, Tokyo (2018)
Horstmann, E., McCabe, M.S., Grochow, L., Yamamoto, S., Rubinstein, L., Budd, T., Shoemaker, D., Emanuel, E.J., Grady, C.: Risks and benefits of phase 1 oncology trials, 1991 through 2002. N. Engl. J. Med. 352(9), 895–904. Correspondence: phase 1 clinical trials oncology. N. Engl. J. Med. 352(23), 2451–2453 (2005)
Hu, F., Rosenberger, W.F.: The Theory of Response-Adaptive Randomization in Clinical Trials. John Wiley & Sons, Hoboken, NJ (2006)
Ivanova, A.: Dose-finding in oncology-nonparametric methods. In: Ting, N. (ed.) Dose Finding in Drug Development, 1st edn, pp. 49–58. Springer, New York, NY (2006)
Kurzrock, R., Benjamin, R.S.: Risks and benefits of phase 1 oncology trials, revisited. N. Engl. J. Med. 352(9), 930–932 (2005)
Lin, Y., Shih, W.J.: Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics 2(2), 203–215 (2001)
Morrissey, K.M., Yuraszeck, T.M., Li, C.-C., Zhang, Y., Kasichayanula, S.: Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities. Clin. Transl. Sci. 9(2), 89–104 (2016)
O’Quigley, J., Chevret, S.: Methods for dose finding studies in cancer clinical trials: a review. Statist. Med. 10(11), 1647–1664 (1991)
O’Quigley, J., Iasonos, A., Bornkamp, B.: Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials, 1st edn. Chapman and Hall/CRC Press, Boca Raton, FL (2017)
O’Quigley, J., Pepe, M., Fisher, L.: Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 46(1), 33–48 (1990)
O’Quigley, J., Zohar, S.: Experimental designs for phase I and phase I/II dose-finding studies. Br. J. Cancer 94(5), 609–613 (2006)
Paoletti, X., Baron, B., Schöffski, P., Fumoleau, P., Lacombe, D., Marreaud, S., Sylvester, R.: Using the continual reassessment method: lessons learned from an EORTC phase I dose finding study. Eur. J. Cancer 42(10), 1362–1368 (2006)
Paoletti, X., Le Tourneau, C., Verweij, J., Siu, L.L., Seymour, L., Postel-Vinay, S., Collette, L., Rizzo, E., Ivy, P., Olmos, D., Massard, C., Lacombe, D., Kaye, S.B., Soria, J.C.: Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey. Eur. J. Cancer 50(12), 2050–2056 (2014)
Pong, A., Chow, S.-C.: Handbook of Adaptive Designs in Pharmaceutical and Clinical Development. Chapman and Hall/CRC Press, Boca Raton, FL (2011)
Postel-Vinay, S., Aspeslagh, S., Lanoy, E., Robert, C., Soria, J.C., Marabelle, A.: Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Ann. Oncol. 27(2), 214–224 (2016)
Potter, D.M.: Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs. J. Biopharm. Stat. 16(5), 579–604 (2006)
Rosenberger, W.F., Haines, L.M.: Competing designs for phase I clinical trials: a review. Statist. Med. 21(18), 2757–2770 (2002)
Storer, B.E.: Design and analysis of phase I clinical trials. Biometrics 45(3), 925–937 (1989)
Tighiouart, M., Rogatko, A.: Dose-finding in Oncology-Parametric Methods. In: Ting, N. (ed.) Dose Finding in Drug Development, 1st edn, pp. 59–72. Springer, New York, NY (2006)
Ting, N.: Dose Finding in Drug Development. Springer, New York, NY (2006)
Tomamichel, M., Jaime, H., Degrate, A., de Jong, J., Pagani, O., Cavalli, F., Sessa, C.: Proposing phase I studies: patients’, relatives’, nurses’ and specialists’ perceptions. Ann. Oncol. 11(3), 289–294 (2000)
Wang, C., Rosner, G.L., Roden, R.B.S.: A Bayesian design for phase I cancer therapeutic vaccine trials. Stat. Med. (2018). https://doi.org/10.1002/sim.8021
Yan, F., Thall, P.F., Lu, K.H., Gilbert, M.R., Yuan, Y.: Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding. Ann. Oncol. 29(3), 694–699 (2018)
Yin, G.: Clinical Trial Design: Bayesian and Frequentist Adaptive Methods. John Wiley & Sons, Hoboken, NJ (2012)
Yuan, Y., Nguyen, H., Thall, P.: Bayesian Designs for Phase I-II Clinical Trials. Chapman and Hall/CRC Press, Boca Raton, FL (2016)
Zhou, H., Yuan, Y., Nie, L.: Accuracy, safety, and reliability of novel phase I trial designs. Clin. Cancer. Res. (2018a). https://doi.org/10.1158/1078-0432.CCR-18-0168
Zhou, H., Murray, T.A., Pan, H., Yuan, Y.: Comparative review of novel model-assisted designs for phase I clinical trials. Statist. Med. 37(14), 2208–2222 (2018b)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2019 The Author(s), under exclusive licence to Springer Japan KK
About this chapter
Cite this chapter
Daimon, T., Hirakawa, A., Matsui, S. (2019). Early-Phase Cancer Clinical Trials. In: Dose-Finding Designs for Early-Phase Cancer Clinical Trials. SpringerBriefs in Statistics(). Springer, Tokyo. https://doi.org/10.1007/978-4-431-55585-8_1
Download citation
DOI: https://doi.org/10.1007/978-4-431-55585-8_1
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-55584-1
Online ISBN: 978-4-431-55585-8
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)